Catalyst Pharmaceuticals Interest Expense 2011-2026 | CPRX

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Catalyst Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
25.7 M	21.1 M	7.7 M	2.88 M	282 K	587 K	1.59 M	1.29 M	454 K	322 K	100 K	76.2 K	47.4 K	15 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
25.7 M	15 K	4.44 M

Quarterly Interest Expense Catalyst Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
4.77 M	3 M	7.92 M	-	6.3 M	1.54 M	1.96 M	-	-833 K	1.81 M	1.7 M	-	905 K	-324 K	93 K	-	68 K	62 K	81 K	-	33 K	111 K	336 K	-	393 K	450 K	343 K	-	344 K	371 K	234 K	-	129 K	91 K	110 K	-	67 K	92.8 K	118 K	-	46.7 K	4.87 K	61.9 K	-	5.92 K	15.7 K	32.8 K	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
7.92 M	-833 K	901 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	722 K	-	-	$ 866 M	China
Apellis Pharmaceuticals APLS	-133 K	$ 20.29	-1.98 %	$ 2.56 B	USA
Axsome Therapeutics AXSM	-15.9 M	$ 166.0	-0.23 %	$ 8.26 B	USA
AbCellera Biologics ABCL	-2.71 M	$ 3.74	-2.23 %	$ 1.12 B	Canada
Certara CERT	6.34 M	$ 7.22	2.34 %	$ 1.16 B	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Eton Pharmaceuticals ETON	1.06 M	$ 17.9	-1.38 %	$ 459 M	USA
Exelixis EXEL	-198 K	$ 40.5	-1.29 %	$ 11 B	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Galectin Therapeutics GALT	1.03 M	$ 2.89	-5.56 %	$ 180 M	USA
Capricor Therapeutics CAPR	399 K	$ 26.3	-2.08 %	$ 704 M	USA
Codexis CDXS	-10.4 M	$ 1.02	-0.33 %	$ 74.9 M	USA
Galapagos NV GLPG	911 K	$ 33.13	-2.82 %	$ 2.69 B	Belgium
Galecto GLTO	1.69 M	$ 29.63	-1.41 %	$ 787 M	Danmark
Halozyme Therapeutics HALO	21.5 M	$ 68.58	-1.82 %	$ 8.22 B	USA
Hoth Therapeutics HOTH	27.1 K	$ 1.0	-1.47 %	$ 6.38 M	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Harmony Biosciences Holdings HRMY	-680 K	$ 28.32	-2.01 %	$ 1.63 B	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
ImmuCell Corporation ICCC	349 K	$ 6.3	-3.67 %	$ 51.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	1.26 M	$ 3.27	-2.1 %	$ 1.17 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Agios Pharmaceuticals AGIO	1.96 M	$ 28.57	-2.16 %	$ 1.66 B	USA
Immunic IMUX	5.02 M	$ 1.13	6.61 %	$ 176 M	USA
Immunovant IMVT	471 K	$ 27.09	-2.38 %	$ 4.11 B	USA
Inhibrx INBX	-580 K	$ 76.39	-1.42 %	$ 3.6 B	USA
InMed Pharmaceuticals INM	431 K	$ 0.8	-2.44 %	$ 1.96 M	Canada